Investor subscribes for SEK 270 m. in a directed new issue in Active Biotech
Investor has entered into an agreement to subscribe for SEK 270 m. in a directed new issue in Active Biotech, paying SEK 45 per share for 6.0 m. shares. Investor’s ownership will amount to 8.0 percent of the capital and votes. The holding in Active Biotech will be reported within Financial Investments.
For further information:
Magnus Dalhammar, Investor Relations Manager, Phone 46 8 614 2130, 46 73 524 2130
Our press releases can be accessed at www.investorab.com
Investor is the leading owner of Nordic-based international companies, founded by the Wallenberg family a hundred years ago. We own significant minority or majority interests in high quality companies. Through our participation on the boards of directors, we work for continuous improvement of the performance of the companies. With our industrial experience, network and financial strength we strive to make our companies best-in-class. Our cash flow allows us to support strategic initiatives in our companies, capture investment opportunities and provide our shareholders with a dividend. Our Core Investments include listed holdings Atlas Copco, ABB, SEB, Ericsson and the operating subsidiary Mölnlycke Health Care.